JCS/T2D JCS/T2D
JCS/T2D JCS/T2D
  • Home
  • About
  • Disclaimer
  • Privacy

Details
By J. Smith
J. Smith
Privacy
07 May 2023
Last Updated: 27 April 2025
Hits: 893
  • Privacy Policy
  • Data Protection
  • User Data
  • Cookie Policy
  • Data Security

Privacy

This privacy policy ("policy") will help you understand how JCS/T2D ("us", "we", "our") uses and protects the data you provide to us when you visit and use [blog URL] ("blog", "service").

We reserve the right to change this policy at any given time, of which you will be promptly updated. If you want to make sure that you are up to date with the latest changes, we advise you to frequently visit this page.

What User Data We Collect

When you visit the site, we may collect the following data:

  • Your IP address.
  • Your contact information and email address (if you provide them).
  • Data profile regarding your online behavior on our site.

Why We Collect Your Data

We are collecting your data for several reasons:

  • To better understand your needs.
  • To improve our services and products.
  • To customize our site according to your online behavior and personal preferences.

Safeguarding and Securing the Data

JCS/T2D is committed to securing your data and keeping it confidential. JCS/T2D has done all in its power to prevent data theft, unauthorized access, and disclosure by implementing the latest technologies and software, which help us safeguard all the information we collect online.

Our Cookie Policy

Once you agree to allow our site to use cookies, you also agree to use the data it collects regarding your online behavior (analyze web traffic, web pages you visit and spend the most time on).

The data we collect by using cookies is used to customize our blog to your needs. After we use the data for statistical analysis, the data is completely removed from our systems.

Please note that cookies don't allow us to gain control of your computer in any way. They are strictly used to monitor which pages you find useful and which you do not so that we can provide a better experience for you.

If you want to disable cookies, you can do it by accessing the settings of your internet browser. You can visit https://www.internetcookies.com, which contains comprehensive information on how to do this on a wide variety of browsers and devices.

Links to Other Websites

Our blog contains links that lead to other websites. If you click on these links JCS/T2D is not held responsible for your data and privacy protection. Visiting those websites is not governed by this privacy policy agreement. Make sure to read the privacy policy documentation of the website you go to from our website.

Distribution of your Personal Data

JCS/T2D will not lease, sell or distribute your personal information to any third parties, unless we have your permission. We might do so if the law forces us.

Articles

  • Professor Juleen R. Zierath: Three Decades of Showing How Exercise Changes Metabolism
  • A More Human View of Glucose: How Hourly Visualizations Reduce Anxiety and Reveal Real Patterns
  • Wegovy Will Not Go OTC: What the Sources Actually Say
  • Bridging Data and Healthcare in the Nordics
  • How Well Do My CGM and BGM Readings Match?
  • Epigenetic Clues to Heart Risk in Type 2 Diabetes
  • Could a Gut Bacterium Help Transform Diabetes and Obesity Care?
  • Why mRNAs Are a Good Option for Vaccines
  • Why I Took Medical Courses to Strengthen My Data Skills
  • New Research Reveals the Hidden Complexity of Insulin Resistance
  • What the 2025 Diabetes Care Updates Mean for You
  • How an Hour-by-Hour View Transforms Time in Range Insights
  • Successfully Completed: Diabetes – A Global Challenge
  • Join the 5K@ADA Virtual Challenge to Promote Diabetes Awareness and Healthy Living
  • How Tirzepatide is Revolutionizing Type 2 Diabetes Prevention in Overweight and Obese Adults
  • Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs
  • FDA Issues Alert on Compounded Semaglutide Dosing Errors
  • Join the 5K@EASD Virtual Challenge to Promote Diabetes Awareness and Healthy Living
  • Regulatory Hurdles for Awiqli: Approval in Canada and EU, Concerns in the US
  • Tirzepatide’s Efficacy in Treating Obstructive Sleep Apnea

News

April 2026

  • New ACHIEVE-4 Data May Help Address FDA Safety Questions on Lilly’s Foundayo
  • Novo Nordisk Expands AI Strategy Through New OpenAI Partnership
  • Lilly’s Foundayo Approval Brings a More Flexible GLP-1 Pill to Weight Loss Care

March 2026

  • Novo Nordisk Reports Promising Phase 2 Data for UBT251 in Type 2 Diabetes
  • Novo Nordisk Expands DTC Push With New Wegovy Subscription Program
  • FDA Approves Awiqli as First Once-Weekly Basal Insulin for Type 2 Diabetes
  • Retatrutide’s First Phase 3 Diabetes Results Draw Attention for More Than Strong Numbers
  • FDA Approves Wegovy HD, Adding a Higher-Dose Semaglutide Option for Obesity
  • Zealand Pharma Reports Phase 2 Results for Petrelintide

February 2026

  • REDEFINE-4 Results: What They Mean for Patients
  • Novo Nordisk Renames Oral Semaglutide as Ozempic Pill Ahead of U.S. Launch

Top Subjects

  • Type 2 Diabetes
  • Novo Nordisk
  • Obesity Treatment
  • GLP-1
  • Wegovy
  • Semaglutide
  • Eli Lilly
  • Tirzepatide
  • Ozempic
  • Zepbound
  • FDA Approval
  • Diabetes
  • Obesity
  • Diabetes Management
  • Continuous Glucose Monitoring
  • Orforglipron
  • Mounjaro
  • Clinical Trials
  • Metabolic Health
  • Obesity Care
  • Dexcom
  • CGM
  • FDA
  • Weight Loss
  • Oral Semaglutide
  • Rybelsus
  • Diabetes Treatment
  • Once-Weekly Insulin
  • Dexcom G7
  • Liraglutide

Contact Us

Search

5K@ADA

5K@EASD

World Obesity Day

Rochen Web Hosting

Bluesky Social

  • You are here:  
  • Home
  • Privacy
  • Privacy
 
Copyright © 2026 JCS/T2D - A Diabetes Journey. All Rights Reserved.
Joomla! is Free Software released under the GNU General Public License.